Table 5.
Subgroup analysis on the association between methylation and OS a
| Symbol | Subgroup | Univariate Cox | Multivariate Cox | Propensity score-1 | Propensity score-2 | ||||
|---|---|---|---|---|---|---|---|---|---|
| Crude HR (95%CI) | P value | Adjusted HR b (95%CI) | P value | Adjusted HR b (95%CI) | P value | Adjusted HR c (95%CI) | P value | ||
| SFRP2 | Age | ||||||||
| < 45 years-old | 0.150 (0.020–1.148) | 0.068 | 0.021 (0.001–0.348) | 0.007 | 0.126 (0.016–1.025) | 0.053 | 0.161 (0.021–1.263) | 0.082 | |
| ≥ 45 years-old | 0.346 (0.160–0.748) | 0.007 | 0.414 (0.188–0.911) | 0.028 | 0.479 (0.221–1.035) | 0.061 | 0.537 (0.246–1.173) | 0.119 | |
| Gender | |||||||||
| Male | 0.373 (0.149–0.935) | 0.035 | 0.357 (0.135–0.945) | 0.038 | 0.471 (0.186–1.197) | 0.113 | 0.551 (0.213–1.427) | 0.219 | |
| Female | 0.214 (0.066–0.698) | 0.011 | 0.311 (0.091–1.056) | 0.061 | 0.328 (0.098–1.102) | 0.071 | 0.291 (0.085–1.005) | 0.051 | |
| Tumor location | |||||||||
| Colon | 0.177 (0.043–0.733) | 0.017 | 0.120 (0.027–0.527) | 0.005 | 0.203 (0.049–0.843) | 0.028 | 0.215 (0.052–0.899) | 0.035 | |
| Rectum | 0.413 (0.178–0.960) | 0.040 | 0.570 (0.237–1.366) | 0.207 | 0.673 (0.291–1.557) | 0.355 | 0.722 (0.308–1.695) | 0.455 | |
| TNM Staging | |||||||||
| I-II | 0.372 (0.132–1.048) | 0.061 | 0.375 (0.126–1.119) | 0.079 | 0.442 (0.156–1.254) | 0.125 | 0.428 (0.150–1.221) | 0.112 | |
| III-IV | 0.311 (0.113–0.859) | 0.024 | 0.280 (0.097–0.809) | 0.019 | 0.374 (0.133–1.048) | 0.061 | 0.452 (0.160–1.272) | 0.132 | |
| Postoperative chemotherapy | |||||||||
| No | 0.249 (0.078–0.797) | 0.019 | 0.284 (0.085–0.945) | 0.040 | 0.381 (0.117–1.239) | 0.109 | 0.365 (0.111–1.203) | 0.098 | |
| Yes | 0.360 (0.142–0.910) | 0.031 | 0.392 (0.150–1.026) | 0.056 | 0.448 (0.177–1.130) | 0.089 | 0.535 (0.207–1.384) | 0.197 | |
| SFRP1+ SFRP2 | Age | ||||||||
| < 45 years-old | 0.150 (0.020–1.148) | 0.068 | 0.021 (0.001–0.348) | 0.007 | 0.119 (0.014–1.025) | 0.053 | 0.151 (0.019–1.225) | 0.077 | |
| ≥ 45 years-old | 0.334 (0.155–0.720) | 0.005 | 0.399 (0.181–0.879) | 0.023 | 0.463 (0.212–1.008) | 0.052 | 0.523 (0.238–1.152) | 0.108 | |
| Gender | |||||||||
| Male | 0.356 (0.143–0.886) | 0.026 | 0.339 (0.130–0.884) | 0.027 | 0.448 (0.179–1.119) | 0.086 | 0.526 (0.206–1.343) | 0.179 | |
| Female | 0.214 (0.066–0.698) | 0.011 | 0.311 (0.091–1.056) | 0.061 | 0.328 (0.098–1.103) | 0.072 | 0.304 (0.090–1.022) | 0.054 | |
| Tumor location | |||||||||
| Colon | 0.177 (0.043–0.733) | 0.017 | 0.120 (0.027–0.527) | 0.005 | 0.200 (0.048–0.832) | 0.027 | 0.213 (0.051–0.890) | 0.034 | |
| Rectum | 0.397 (0.172–0.918) | 0.031 | 0.546 (0.227–1.312) | 0.176 | 0.656 (0.278–1.551) | 0.337 | 0.708 (0.297–1.690) | 0.437 | |
| TNM Staging | |||||||||
| I-II | 0.372 (0.132–1.048) | 0.061 | 0.375 (0.126–1.119) | 0.079 | 0.445 (0.157–1.260) | 0.127 | 0.434 (0.152–1.237) | 0.118 | |
| III-IV | 0.295 (0.108–0.809) | 0.018 | 0.263 (0.092–0.751) | 0.013 | 0.352 (0.127–0.970) | 0.044 | 0.419 (0.147–1.193) | 0.103 | |
| Postoperative chemotherapy | |||||||||
| No | 0.249 (0.078–0.797) | 0.019 | 0.284 (0.085–0.945) | 0.040 | 0.381 (0.117–1.239) | 0.109 | 0.360 (0.109–1.191) | 0.094 | |
| Yes | 0.343 (0.137–0.861) | 0.023 | 0.372 (0.144–0.961) | 0.041 | 0.426 (0.168–1.076) | 0.071 | 0.517 (0.200–1.332) | 0.172 | |
aAll HR values were referenced by hypomethylation
bControlling for the variables which included age, gender, CEA, CA19–9, TNM staging, pathological classification, differentiation degree and postoperative radiotherapy
cControlling for the variables which included age, gender, CEA, CA19–9, multiple polyps, tumor location, TNM staging, pathological classification, histologic classification, differentiation degree, postoperative chemotherapy and postoperative radiotherapy